Spinal Cord Stimulation Devices Market: Rising Prevalence of Chronic Pain Disorders to Drive Market Growth to US$ 6,211.8 Million by 2033

As per the latest market research by Business Market Insights (BMI), the research report "Spinal Cord Stimulation Devices Market Size and Forecast (2026–2033)" forecasts how the market is set to surge 94.15% by 2033. The global spinal cord stimulation (SCS) devices market is driven by the increasing prevalence of chronic pain disorders, growing demand for non-opioid pain management therapies, and rising adoption of minimally invasive neuromodulation procedures. Technological advancements such as rechargeable implants, closed-loop stimulation, and MRI-compatible systems are improving treatment outcomes and patient acceptance. Additionally, expanding clinical evidence, favorable reimbursement policies in developed markets, and an aging population are further supporting market growth.

The report forecasts the market to expand from US$ 3,199.5 million in 2025 to US$ 6,211.8 million by 2033, registering a robust CAGR of 8.6% over the 2026–2033 period.

The spinal cord stimulation devices market is experiencing remarkable growth owing to the rising prevalence of chronic pain disorders and a rising inclination towards non-drug-based solutions. The functioning of spinal cord stimulation devices involves the transmission of electrical signals into the spinal cord to block pain signals before reaching the brain; the devices are useful in treating chronic pain disorders like failed back surgery syndrome, complex regional pain syndrome, and chronic neuropathic pain. The key factors driving growth include technological improvements in the form of rechargeable neurostimulators, closed-loop technology, wireless programming, and MRI compatibility for safety and efficacy. The rising apprehensions about opioid addiction and extended usage of medications have also contributed to an increased uptake of neuromodulation therapy.

Overview of report findings

Market Growth

The spinal cord stimulation devices market is projected to grow from US$ 3,199.5 million in 2025 to US$ 6,211.8 million by 2033, registering a compound annual growth rate (CAGR) of 8.6% between 2026 and 2033.

The worldwide spinal cord stimulation systems industry is fueled by the escalating incidence of chronic pain conditions, high requirement for non-opioid pain management treatments, and increased adoption of minimally invasive neuromodulation techniques. Innovations like rechargeable implantable technology, closed-loop systems, and MRI-compatible stimulators have been adding to the growth trend. Other factors contributing to this include increasing clinical studies on the benefits of using such stimulators and a positive reimbursement environment in developed regions.

Rising Prevalence of Chronic Pain Disorders

Increased prevalence rates of chronic pain disorders are one of the factors contributing to the growth of the spinal cord stimulation devices market. Chronic pain conditions like Failed Back Surgery Syndrome (FBSS), chronic lower back pain, complex regional pain syndrome, peripheral neuropathy, and many other neuropathic pain syndromes affect a large number of individuals across the globe, and the consequences can be serious. For many of these patients, standard pain treatments like medication, physical therapy, and surgery have proven to be insufficient. Therefore, physicians need alternative approaches that may help provide better results, including spinal cord stimulation (SCS) therapy. Research proves that SCS is capable of relieving pain symptoms, improving functional outcomes, and enhancing quality of life. In addition, due to higher rates of degenerative spine diseases in an increasingly aging population, more individuals may be at risk. Consequently, rising awareness about neuromodulation therapies among physicians and patients may contribute to increased adoption of SCS devices.

Growing Demand for Non-Opioid Pain Management

The growing demand for non-opioid pain management solutions is significantly driving the spinal cord stimulation devices market. Concerns regarding opioid addiction, overdose risks, side effects, and long-term dependency have prompted healthcare systems to seek alternative approaches for managing chronic pain. Spinal cord stimulation offers a drug-free treatment option that directly targets pain pathways through electrical stimulation, reducing reliance on opioid medications. Clinical studies have demonstrated that SCS therapy can provide meaningful and sustained pain relief for many patients while improving daily functioning and overall quality of life. Governments, healthcare organizations, and professional societies are increasingly promoting non-opioid pain management strategies, further supporting adoption. Technological innovations such as high-frequency stimulation, burst stimulation, and closed-loop systems have enhanced therapeutic effectiveness and expanded the range of patients who may benefit from treatment. As healthcare providers continue to prioritize safer and more sustainable chronic pain management approaches, the demand for spinal cord stimulation devices is expected to grow considerably across global markets.

Geographic Insights

North America dominates the spinal cord stimulation devices market due to the high prevalence of chronic pain conditions, strong reimbursement coverage, and widespread adoption of advanced neuromodulation technologies. The region benefits from well-established pain management centers, robust healthcare infrastructure, and the presence of leading medical device manufacturers. Increasing physician awareness, growing acceptance of non-opioid treatment approaches, and continuous technological innovation continue to support market leadership across the United States and Canada.

Europe is the second-largest spinal cord stimulation devices market, supported by increasing demand for chronic pain management therapies and strong healthcare systems. The region has witnessed growing adoption of neuromodulation technologies as clinicians seek alternatives to long-term pharmacological treatment. Favorable healthcare funding mechanisms, expanding clinical evidence, and rising awareness regarding the benefits of spinal cord stimulation are contributing to growth. Germany, the United Kingdom, France, and Italy remain key regional markets.

Asia Pacific is the fastest-growing spinal cord stimulation devices market due to increasing healthcare expenditure, rising prevalence of chronic pain disorders, and expanding access to advanced medical technologies. Growing awareness of neuromodulation therapies among healthcare professionals and patients is supporting adoption. Countries such as China, Japan, India, and South Korea are investing heavily in healthcare infrastructure and specialized pain management services, creating significant growth opportunities for spinal cord stimulation device manufacturers.

Market Segmentation

• By product type, the spinal cord stimulation devices market is segmented into rechargeable spinal cord stimulators and non-rechargeable spinal cord stimulators. The rechargeable spinal cord stimulators segment dominated the market in 2025. This is driven by their longer device lifespan, reduced replacement surgeries, and growing preference for cost-effective long-term pain management solutions.
• Based on type, the spinal cord stimulation devices market is segmented into invasive and noninvasive. The invasive segment dominated the market in 2025. The dominance of this segment is attributed to its superior clinical efficacy, targeted stimulation capabilities, and established use in chronic pain treatment.
• On the basis of application, the spinal cord stimulation devices market is classified into pain & sensory modulation, functional disorders, and other applications. The pain & sensory modulation segment dominated the market in 2025. This is driven by the increasing prevalence of chronic pain conditions and rising demand for non-opioid pain management therapies.
• In terms of end user, the spinal cord stimulation devices market is categorized into hospitals, specialty clinics, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2025. This is driven by the availability of advanced implantation facilities, skilled specialists, and comprehensive patient care services.

Competitive Strategy & Development

Key Players: The spinal cord stimulation devices market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Medtronic
2. Abbott
3. Boston Scientific Corporation
4. Biotronik
5. Nevro Corp
6. Saluda Medical Pty Ltd.
7. Nevro Corp
8. Beijing PINS Medical Co., Ltd. 
9. ONWARD Medical
10. Soterix Medical Inc

Trending Topics: Closed-Loop Spinal Cord Stimulation, High-Frequency Spinal Cord Stimulation, Burst Stimulation Therapy, Rechargeable Neurostimulators, MRI-Compatible SCS Systems, Wireless Programming Platforms, Dorsal Root Ganglion Stimulation, AI-Enabled Pain Management Systems, Miniaturized Implantable Neurostimulators, Remote Monitoring Technologies, Personalized Neuromodulation Therapy, and Adaptive Spinal Cord Stimulation.

Global Headlines

• Medtronic plc received U.S. FDA approval for its Inceptiv™ Closed-Loop Spinal Cord Stimulator – In April 2024, ⁠Medtronic plc, announced that it received U.S. FDA approval for its Inceptiv™ Closed-Loop Spinal Cord Stimulator. This system marks the company's first rechargeable closed-loop SCS device that senses real-time biological signals along the spinal cord and automatically adjusts stimulation parameters.
• ONWARD Medical received an Investigational Device Exemption approval for its ARC-IM® System – In October 2025, ONWARD Medical, announced that it received an Investigational Device Exemption (IDE) approval from the U.S. FDA for its ARC-IM® System. This milestone clearance allows the company to initiate its global pivotal "Empower BP" clinical study to assess the safety and efficacy of their implantable spinal cord stimulation platform.

Conclusion

The global spinal cord stimulation devices market is poised for strong growth as healthcare providers increasingly adopt non-opioid therapies for chronic pain management. Rising prevalence of neuropathic pain disorders, failed back surgery syndrome, and degenerative spinal conditions continues to expand the patient population eligible for SCS therapy. Technological advancements such as closed-loop systems, high-frequency stimulation, and MRI-compatible devices are improving treatment efficacy and patient outcomes. North America remains the leading market due to favorable reimbursement policies and advanced healthcare infrastructure, while Europe maintains substantial demand through established pain management programs. Asia Pacific is expected to register the fastest growth, driven by expanding healthcare access and increasing awareness of neuromodulation therapies. Continued innovation and growing clinical acceptance are expected to create significant opportunities for market participants in the coming years.